<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02807779</url>
  </required_header>
  <id_info>
    <org_study_id>15-17251</org_study_id>
    <secondary_id>1R01HL128816-01</secondary_id>
    <nct_id>NCT02807779</nct_id>
  </id_info>
  <brief_title>Intima Versus Adventitia Drug Delivery to Elucidate Mechanisms of Restenosis: Magnetic Resonance Imaging</brief_title>
  <acronym>INVADER MRI</acronym>
  <official_title>Intima Versus Adventitia Drug Delivery to Elucidate Mechanisms of Restenosis: Magnetic Resonance Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter, randomized trial to determine the mechanisms of vascular&#xD;
      healing. The study will evaluate subjects with peripheral artery disease (PAD) who require an&#xD;
      endovascular intervention of the femoro-popliteal (SFA) artery to restore blood flow to the&#xD;
      leg.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peripheral artery disease (PAD) affects at least 12 million Americans annually with more than&#xD;
      half a million patients undergoing an endovascular or surgical revascularization procedure in&#xD;
      order to treat the disease. Unfortunately, about two-thirds of patients still have blockages&#xD;
      in the leg arteries, even after these procedures.&#xD;
&#xD;
      Advances in Magnetic resonance imaging (MRI) offer promise for understanding the mechanism of&#xD;
      failure through insights into vessel wall composition, remodeling, and inflammation.&#xD;
      Restenosis has a known relationship to inflammation. Advances in micro-catheter technologies&#xD;
      offer the ability to deliver anti-inflammatory medications such as Dexamethasone (DEX)&#xD;
      directly to the adventitia and advances in drug delivery on balloon surfaces to deliver&#xD;
      paclitaxel to the intima of the artery.&#xD;
&#xD;
      This study aims to investigate if patient-specific parameters affect angioplasty outcomes, if&#xD;
      DEX has a biological effect on the vessel wall, and if this effect is through the reduction&#xD;
      of inflammation.&#xD;
&#xD;
      In response to an FDA issued &quot;Letter to Healthcare Providers&quot; dated August 9, 2019 that&#xD;
      reported the &quot;relative risk for increased mortality at 5 years was 1.57 (95% confidence&#xD;
      interval 1.16 - 2.13), which corresponds to a 57% relative increase in mortality in patients&#xD;
      treated with paclitaxel-coated devices,&quot; participant enrollment in the paclitaxel drug coated&#xD;
      balloon arm was stopped and a plain balloon angioplasty arm was added to the protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 10, 2016</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Actual">October 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Percent Wall Volume (PWV)</measure>
    <time_frame>From Post-Operative Day One to 12 Months</time_frame>
    <description>Percent Wall Volume (PWV) of the treated segment of artery will be measured by MRI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in wall volume (WV) without a change in total vessel volume (TVV)</measure>
    <time_frame>From Post-Operative Day One to 12 Months</time_frame>
    <description>As measured by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in perioperative inflammatory profile (MCP-1)</measure>
    <time_frame>From Post-Operative Day One to 12 Months</time_frame>
    <description>As measured by serum MCP-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in perioperative inflammatory profile (CRP)</measure>
    <time_frame>From Post-Operative Day One to 12 Months</time_frame>
    <description>As measured by serum CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in perioperative inflammatory profile (IL-1beta)</measure>
    <time_frame>From Post-Operative Day One to 12 Months</time_frame>
    <description>As measured by serum IL-1beta</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ktrans</measure>
    <time_frame>From 1 Month to 6 Months</time_frame>
    <description>As measured by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lumen volume (LV) relative to total vessel volume (TVV)</measure>
    <time_frame>From Post-Operative Day One to 12 Months</time_frame>
    <description>As measured by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with clinically significant restenosis that undergo reintervention of greater than or equal to 75% of the treated segment</measure>
    <time_frame>From Post-Operative Day One to 12 Months</time_frame>
    <description>As the subject undergoes reintervention, any treatment that overlaps with greater than or equal to 75% of the segment initially treated by the index procedure (treated segment) may result in obfuscation of the primary outcome measure .</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Extended Clinical Adverse Events Monitoring</measure>
    <time_frame>From Post-Operative Day One to 36 Months</time_frame>
    <description>Participant monitoring for clinical adverse events</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <condition>Vascular Disease</condition>
  <condition>Critical Limb Ischemia</condition>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to the Dexamethasone group will receive dexamethasone infusion to the adventitia of the artery following plain-old-balloon-angioplasty (POBA).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug Coated Balloon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized to the Drug Coated Balloon (DCB) group will not receive dexamethasone infusion to the adventitia of the artery following (POBA). They will receive additional angioplasty with a paclitaxel coated balloon.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plain Balloon Angioplasty</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomized to the Plain Balloon Angioplasty will receive balloon angioplasty (POBA) only. They will not receive adventital dexamethasone or paclitaxel.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone infusion</intervention_name>
    <description>Participants will receive dexamethasone infusion following plain balloon angioplasty</description>
    <arm_group_label>Dexamethasone</arm_group_label>
    <other_name>microinfusion catheter</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug coated balloon</intervention_name>
    <description>Participants will receive angioplasty with a drug-coated balloon following plain balloon angioplasty</description>
    <arm_group_label>Drug Coated Balloon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Plain balloon angioplasty</intervention_name>
    <description>Participants will receive plain balloon angioplasty only</description>
    <arm_group_label>Plain Balloon Angioplasty</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Screening:&#xD;
&#xD;
          1. Male or non-pregnant female ≥ 35 years of age&#xD;
&#xD;
          2. Atherosclerotic, infrainguinal PAD&#xD;
&#xD;
          3. Rutherford Clinical Category 2-6&#xD;
&#xD;
          4. Stenosis detected by radiology that in the clinician's opinion is the reason for the&#xD;
             PAD symptoms&#xD;
&#xD;
          5. Patient is willing to provide informed consent and comply with the required follow up&#xD;
             visits, testing schedule, and medication regimen&#xD;
&#xD;
          6. Estimated Glomerular Filtration Rate (eGFR) ≥ 30 and/or threshold established by the&#xD;
             local Institutional Review Board or Committee of Human Research&#xD;
&#xD;
        Procedural Criteria:&#xD;
&#xD;
          1. De novo atherosclerotic lesion qualifying for angioplasty&#xD;
&#xD;
          2. A patent artery proximal to the index lesion. Concomitant inflow procedures, including&#xD;
             open femoral artery endarterectomy and/or stenting of the iliac arteries, are&#xD;
             permissible.&#xD;
&#xD;
          3. &gt;50% diameter stenosis of the superficial femoral artery and/or popliteal artery&#xD;
             (between the profunda and tibioperoneal trunk)&#xD;
&#xD;
          4. Reference vessel diameter ≥3 mm and ≤ 8mm&#xD;
&#xD;
          5. Successful wire crossing of lesion&#xD;
&#xD;
          6. Successful angioplasty of the index lesion or part of the index lesion, defined as&#xD;
             ≤30% residual lumen stenosis compared with adjacent non-diseased lumen diameter,&#xD;
             without flow-limiting dissection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Screening Criteria:&#xD;
&#xD;
          1. Any contraindication to receiving an MRI&#xD;
&#xD;
          2. Pregnant, nursing, or planning on becoming pregnant in &lt; 2yrs&#xD;
&#xD;
          3. Life expectancy of &lt; 1 yr&#xD;
&#xD;
          4. History of solid organ transplantation&#xD;
&#xD;
          5. Patient actively participating in another investigational device or drug study&#xD;
&#xD;
          6. History of hemorrhagic stroke within 3 months of index procedure&#xD;
&#xD;
          7. Previous or planned surgical or interventional procedure within 30 days of index&#xD;
             procedure&#xD;
&#xD;
          8. Chronic renal insufficiency with eGFR &lt; 30&#xD;
&#xD;
          9. Prior bypass surgery, stenting, atherectomy or angioplasty of the index lesion&#xD;
&#xD;
         10. Inability to take required study medications&#xD;
&#xD;
         11. Contra-indication or known hypersensitivity to dexamethasone sodium phosphate,&#xD;
             contrast media, gadolinium, aspirin or Plavix&#xD;
&#xD;
         12. Systemic fungal infection&#xD;
&#xD;
         13. Acute limb ischemia&#xD;
&#xD;
         14. Prior participation of the index limb in the current study (contralateral treatment is&#xD;
             allowed)&#xD;
&#xD;
         15. Patient is being treated with long-term steroids (not including treatment of a&#xD;
             bronchial condition with inhaled steroids)&#xD;
&#xD;
        Procedural Criteria:&#xD;
&#xD;
          1. Index lesions extending into the tibial trifurcation or above the profunda. Note: the&#xD;
             outflow tibial artery can be treated concomitantly. Similarly, the common femoral&#xD;
             artery can be treated concomitantly, either with open endarterectomy and patch&#xD;
             angioplasty or with endovascular methods. However, the index lesion cannot be&#xD;
             contiguous with either the CFA or the tibial trifurcation.&#xD;
&#xD;
          2. Circumferential calcification at index lesion, which in the judgment of the&#xD;
             investigator would prevent penetration of the Micro-Infusion catheter needle through&#xD;
             the vessel wall&#xD;
&#xD;
          3. Inadequate distal outflow defined as no patent tibial arteries (&gt;50% stenosis). The&#xD;
             outflow vessel can be established at the time of primary treatment&#xD;
&#xD;
          4. Use of adjunctive therapies other than angioplasty. Chocolate balloons and/or scoring&#xD;
             balloons are allowed, if used below reference diameter.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Warren Gasper, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Francisco VA Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Saloner, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Francisco VA Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Francisco VA Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 1, 2016</study_first_submitted>
  <study_first_submitted_qc>June 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2016</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>angioplasty</keyword>
  <keyword>peripheral artery disease</keyword>
  <keyword>peripheral vascular disease</keyword>
  <keyword>atherosclerosis</keyword>
  <keyword>balloon angioplasty</keyword>
  <keyword>dexamethasone</keyword>
  <keyword>drug coated balloon</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>walking</keyword>
  <keyword>claudication</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 10, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT02807779/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

